Search

Displaying results 4301 - 4310 of 8700 in total
  1. Drug

    LC16M8

    go.drugbank.com/drugs/DB05019
    Investigational

    It is the only attenuated vaccine to be licensed for use in humans to prevent smallpox infection.

  2. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules. … CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.

  3. Drug

    Pralidoxime

    go.drugbank.com/drugs/DB00733
    ApprovedInvestigationalVet approved

    Pralidoxime is an antidote to organophosphate pesticides and chemicals.

  4. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment … The drug is composed of an IL-6–binding trimer and a IgG-binding domain.

  5. Drug

    Glycylglutamine

    go.drugbank.com/drugs/DB15990
    Investigational

    Mixtures: GLAMIN SOLUTION FOR INFUSION, Trimix MOF Emulsion zur Infusion
  6. Drug

    BMS-564929

    go.drugbank.com/drugs/DB07286
    Experimental

    BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). … So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.

  7. Drug

    SX-682

    go.drugbank.com/drugs/DB19210
    Investigational

    clinical trial NCT04574583 (Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With Bintrafusp Alfa (M7824 or Tgf-beta "Trap"/pd-l1

  8. Drug

    Froniglutide

    go.drugbank.com/drugs/DB16178
    Investigational

    Glymera is under investigation in clinical trial NCT01658501 (Phase 2b Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of

  9. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  10. Drug

    Orlistat

    go.drugbank.com/drugs/DB01083
    ApprovedInvestigational

    It was approved by the FDA for use in combination with a reduced-calorie diet in 1999.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers